News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
First Trust Advisors LP has invested $1.03 million in NovoCure Limited by acquiring 94,293 shares. Institutional investors collectively own 84.61% of the company, and NovoCure recently reported strong quarterly revenue and a better-than-expected adjusted loss. Analysts currently maintain a "Hold" rating for the stock …
NovoCure (NVCR) is experiencing renewed optimism due to its tumor treating fields devices and hopes for upcoming FDA approval, leading to a recent surge in its stock price. Despite significant short-term gains, the stock has seen declines over three and five years. Analysts consider …
Wall Street Zen has upgraded NovoCure (NASDAQ:NVCR) to a "Buy" rating, despite a broader analyst consensus of "Hold" with an average price target of $21.20. The upgrade follows NovoCure's strong quarterly results, where adjusted EPS loss of $0.13 significantly beat the anticipated $0.33 loss, …
Novocure Ltd (NVCR) saw its stock surge to $19.91 following stronger-than-expected Q2 2026 earnings. The company reported revenue that exceeded consensus estimates, growing 8.6% year-over-year. This recovery is primarily attributed to the FDA approval and multi-indication expansion of its Optune Pax treatment, especially after …
NovoCure (NVCR) stock has seen a 90% decline over the past five years, yet recent valuations suggest it may be undervalued, particularly on a price-to-sales basis. The company's progress in Tumor Treating Fields therapies and record quarterly sales point to potential upside, though legal …
This article provides a comprehensive stock analysis of Novocure Ltd (NVCR), highlighting its relatively healthy fundamentals, high growth potential with 28.67% average revenue growth over three years, and fair valuation. Despite a recent weak stock market performance, the company shows strong fundamentals and has …
This article provides a revenue breakdown for NovoCure Ltd. (DUS:038), showing that the company generated EUR 557.98 million last year, primarily from its Tumor Treating Fields segment. The United States was the largest contributor to revenue, accounting for EUR 328.33 million. The previous year's …
This article provides a technical analysis of Novocure Ltd (NVCR), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. According to the analysis, NVCR is suitable for range-bound swing trading, with its price momentum …
Novocure (NVCR) reported record quarterly revenue of US$183.6 million in Q2 2026 and raised its full-year 2026 guidance to US$710-725 million. The company's Optune Pax therapy received CE Mark approval for pancreatic cancer, facilitating its first European launch in Germany, and active patient numbers …
This article analyzes the market sentiment for NovoCure (NVCR) based on key indicators including analyst consensus, short interest, options flow, and insider activity. It highlights that while analysts largely recommend a "Buy," the options flow suggests a bearish sentiment, and the short interest is …
This article provides an overview of Novocure Ltd (NVCR)'s dividend and stock split history, indicating that no dividends have been distributed in the past five years. It also includes current stock performance data and company information. The page states that investment products carry significant …
Novocure (NVCR:NASDAQ) reported record Q2 2026 revenue of US$183.6 million, a 16% increase year-over-year, leading the company to raise its full-year guidance to US$710-US$725 million. The oncology company also announced the CE Mark approval for Optune Pax for pancreatic cancer and saw its net …
NovoCure (NVCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings …
NovoCure (NVCR) closed the last trading session at $17.65, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …
Have you evaluated the performance of NovoCure's (NVCR) international operations for the quarter ending June 2026? Given the extensive global presence of this oncology drug developer, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. The …
NovoCure (NVCR) saw its stock rise 10.9% after reporting its strongest Q2 ever, with a revenue increase to US$183.58 million, a reduced net loss, and an upgraded 2026 revenue outlook of US$710-US$725 million. The company also secured a CE Mark for its Optune Pax …
NovoCure's Q2 2026 earnings call revealed a cautiously optimistic outlook, with record net revenue and positive adjusted EBITDA, signaling a shift towards profitability. Despite these achievements, the company acknowledged ongoing challenges such as reimbursement hurdles and the need to increase prescriber engagement. Key drivers …
NovoCure (NVCR) has raised its 2026 net revenue guidance to $710-$725 million after a quarter of record sales and active patient growth, leading to a significant rebound in share price over the past year. Despite this positive momentum, longer-term shareholder returns remain negative, prompting …
NovoCure (NasdaqGS:NVCR) is forecast to grow earnings and revenue by 54.6% and 16.5% per annum respectively. Recent updates include a price target increase to US$27.14 and revised revenue guidance for 2026, driven by the launch of Optune Pax in Germany and growing active patient …
Despite reporting its strongest-ever commercial quarter with record revenues and active patients, NovoCure's stock (NVCR) experienced a decline. The company surpassed Q2 earnings and revenue estimates and raised its fiscal 2026 revenue guidance. However, the stock slid due to disappointing Phase 3 TRIDENT trial …
Wedbush has reiterated its "Neutral" rating for Novocure. This article likely reports on an analyst's updated stance on the company's stock.
H.C. Wainwright has reduced its price target for NovoCure Ltd. (NASDAQ:NVCR) to $32 from $46, while maintaining a Buy rating. This adjustment comes despite NovoCure reporting stronger-than-expected second-quarter 2026 revenues and raising its full-year revenue and adjusted EBITDA guidance. The company's impressive gross profit …
NovoCure (NVCR) shares surged after Q2 2026 earnings, pushing past technical resistance and shifting investor focus from a past clinical trial failure to the commercial potential of its Optune Pax platform. The Q2 results reflect the first full quarter of Optune Pax revenue, a …
Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval for its brain therapy candidate. In intra-day trading, the stock climbed to a …
Novocure reported strong second quarter 2026 financial results with record net revenues of $184 million, a 16% increase year-over-year, driven by 18% global active patient growth. The company also received CE Mark approval for Optune Pax® for locally advanced pancreatic cancer in the EU, …
NovoCure (Nasdaq: NVCR) saw its share price jump by nearly 25% after reporting strong Q2 2026 results, handily beating analyst estimates on both revenue and earnings. The company reported $184 million in revenue, a 16% increase year-over-year, and narrowed its net loss to $15 …
This article lists 12 healthcare stocks experiencing significant movement during Thursday's intraday trading session. It highlights several gainers, including NovoCure, Zhengye Biotechnology, Neuphoria Therapeutics, Medpace Holdings, Gelteq, and Advanced Biomed, along with their respective percentage increases and market capitalizations. Conversely, it also details losers …
Novocure reported record second-quarter net revenue of $183.6 million, a 16% increase year-over-year, driven by the expansion of its TTFields therapy. The company also raised its 2026 revenue guidance to $710 million-$725 million and improved its adjusted EBITDA outlook, fueled by the commercial growth …
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …
Novocure Ltd (NASDAQ: NVCR) exceeded analyst expectations in its second-quarter earnings, reporting an EPS of $-0.13, which was $0.20 better than the estimated $-0.33. The company also surpassed revenue estimates, bringing in $183.6M against a consensus of $172.72M. Novocure provided a strong revenue guidance …
Search by ticker symbol or company name and select a result to open its chart.